Biocon Biologics

Biocon Biologics names Deepali Naair as Global Head, Brand & Corp Comm

With over three decades of experience across India, ASEAN, and Australia, Deepali Naair brings deep expertise in brand building, marketing, and corporate reputation.

Biocon Biologics' success in biosimilars points to the future pathway for Indian pharma

Biosimilars a huge opportunity, and also a challenge for Indian drugmakers

Biocon Biologics' Bengaluru unit classified as voluntary action indicated by USFDA

Under voluntary action indicated (VAI), while objectionable conditions were found and documented during an inspection, the agency is not prepared to take or recommend regulatory action

Biocon Biologics secures USFDA approval for biosimilar product to treat ophthalmology conditions

The US Food and Drug Administration (USFDA) has approved the company's first-to-file application for Yesafili, a vascular endothelial growth factor inhibitor used to treat several different types of ophthalmology conditions, the company said in a statement.

Biocon stock falls 4% after subsidiary sells branded formulations biz to Eris Lifesciences

Biocon Biologics said that it has entered into a long-term commercial collaboration with Eris Lifesciences to expand patient access to its portfolio of Metabolics, Oncology, and Critical Care products in India.

Eris Lifesciences’ insatiable appetite for growth is driving up its debt

After Biocon Biologics' formulation deal, net debt at the company is estimated to rise from Rs 886 crore to Rs 2,400 crore

Biocon Biologics signs 10-year supply deal with Eris Lifesciences for Rs 1242 crore

As part of the deal over 430 employees associated with the business are expected to transition to Eris

Biocon Biologics settles patent issue; paves way for launch of biosimilar product in Canada

The settlement pact paves the way for the introduction of Yesafili, a proposed biosimilar to Eeylea (aflibercept) injection, in the Canadian market, Biocon Biologics said in a regulatory filing.

Biocon Biologics inks pact with Sandoz for sale of 2 biosimilar products in Australia

The agreement provides Sandoz the exclusive rights to promote, sell and distribute biosimilars Trastuzumab and Bevacizumab in Australia, Biocon Biologics said in a statement.

Biocon Biologics, Sandoz sign pact to distribute adalimumab biosimilar Humira in Japan

Adalimumab BS for subcutaneous injection is a biosimilar of Humira, offering therapeutic solutions for immune-related diseases such as rheumatoid arthritis, psoriasis vulgaris, ankylosing spondylitis, Crohn's disease and ulcerative colitis

Biocon Biologics completes integration of Viatris' biosimilar business in 120 countries

Earlier in 2023, the integration process included over 70 emerging markets in July, the North America business in September, and the European business in November

Eris Lifesciences to buy Biocon arm’s derma, nephro units; Eris, Biocon shares in focus

Eris Lifesciences has signed a definitive agreement with Biocon Biologics to acquire its Branded Formulations’ India (BFI) business units of nephrology and dermatology.

Eris acquires nephrology, dermatology brands of Biocon for Rs 366 crore

The deal will be funded partly through debt financing. The transaction is expected to achieve financial closure by the end of 2023.

Biocon may list biosimilars business by 2025 first half - CEO

Biocon Biologics, a fully integrated subsidiary of Biocon Ltd, focuses on making biosimilars, with key revenue-generating markets being the United States and Europe.

Biocon gets 8 observations from USFDA after inspection of Malaysia insulins facility

The US drug regulator issued 6 observations for Drug Substance, Drug Product units and Quality Control laboratories and 2 observations for the Delivery Devices unit.

Biocon gains as arm takes over commercialization of biosimilars business

Biocon Biologics had signed a deal to acquire Viatris Inc's biosimilars business for $3.33 billion in February 2022

Biocon Biologics takes over Viatris' biosimilar business in over 70 countries

Following the deal closure in November 2022, this marks the first wave of countries where Viatris' operations have fully transitioned to Biocon Biologics, the company said in a statement.

Biocon Biologics biosimilar to treat certain inflammatory diseases now available in US

The company said HULIO (adalimumab) injection, a biosimilar to Humira (adalimumab), is now available to patients in the US after five years of experience in Europe and two years in Canada.

Diabetes and cardiovascular diseases account for over 33% of Jan Aushadhi medicine sales, reveals govt data

Ravi Dadhich, chief, Jan Aushadhi Yojana, said that the generic medical outlets under Pradhan Mantri Bhartiya Jan Aushadhi Pariyojana (PMBJP) record Telmisartan, Amlodipine and Metformin among their top-selling drugs.

Biocon Biologics elevates Shreehas Tambe as MD & CEO

Tambe was Deputy CEO of Biocon Biologics, a subsidiary of Bengaluru-based Biocon.

Biocon Biologics completes acquisition of Viatris' global biosimilars business

In February this year, Biocon Biologics inked a pact to acquire Viatris Inc's biosimilars business for consideration of up to USD 3.33 billion (about Rs 24,990 crore).

Biocon Biologics inks out-licensing agreement with Yoshindo Inc

Under the terms of this deal, Japan-based Yoshindo gets exclusive commercialisation rights in Japan for Ustekinumab and Denosumab -- developed and manufactured by Biocon Biologics -- for an addressable market opportunity of USD 700 million, Biocon Biologics said in a statement.